Metagenics, a leader in science-based health and wellness solutions, has acquired Symprove, a UK-based biotech company specializing in gut health, for an undisclosed amount. This acquisition marks a significant move for Metagenics to expand its presence in the rapidly growing microbiome market and integrate Symprove's scientifically validated product into its portfolio.
Symprove, launched in 2002, has established itself with a unique water-based live bacteria supplement designed to survive stomach acid and reach the gut alive. The company has garnered recognition for its efficacy, supported by independent trials, including one at King’s College London, where it outperformed other leading products. Symprove has experienced rapid growth, being named a fastest-growing biotech business by the Sunday Times Fast Track 100, with an annual growth rate of 50%. Its holistic approach to gut health, coupled with a supportive community and expert-led content, has resonated with consumers seeking solutions for gut issues.
The acquisition is strategically aligned with Metagenics' commitment to providing evidence-based health solutions. Symprove's strong scientific foundation and proven market success offer a complementary addition to Metagenics' existing offerings. This integration is expected to create synergies by leveraging Metagenics' broader resources and distribution capabilities to accelerate Symprove's mission of improving gut health for more individuals. The move positions the combined entity to capitalize on the increasing consumer interest in the link between diet, exercise, and the microbiome.
By bringing Symprove under its umbrella, Metagenics aims to strengthen its market leadership in the wellness sector. The combined expertise and product innovation are anticipated to enhance the development of advanced gut health solutions, addressing the evolving needs of consumers globally. This acquisition underscores a shared vision to deliver impactful, science-backed products that contribute to overall well-being.